Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$15.13 USD
-0.17 (-1.11%)
Updated Oct 2, 2024 10:02 AM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Cash flow Statements
Fiscal Year End for Pacira BioSciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 41.96 | 15.91 | 41.98 | 145.52 | -11.02 |
Depreciation/Amortization & Depletion | 79.32 | 98.71 | 54.45 | 40.32 | 35.03 |
Net Change from Assets/Liabilities | -45.78 | -45.91 | -19.66 | -19.18 | 7.90 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 79.15 | 76.57 | 48.95 | -89.63 | 38.61 |
Net Cash From Operating Activities | 154.65 | 145.27 | 125.72 | 77.03 | 70.52 |
Property & Equipment | -15.16 | -30.08 | -45.87 | -37.80 | -10.16 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -32.00 | -420.04 | 0.00 | -117.69 |
Investments | 92.70 | -163.11 | 449.12 | -239.81 | -0.64 |
Other Investing Activities | 0.00 | 0.00 | -4.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 77.54 | -225.19 | -20.79 | -277.61 | -128.49 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 4.75 | 27.34 | 26.66 | 47.76 | 10.87 |
Issuance (Repayment) of Debt | -180.76 | -427.69 | 363.75 | 192.62 | -0.57 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -7.02 | -1.18 | -9.71 | -18.08 | -6.63 |
Net Cash from Financing Activities | -183.03 | -401.53 | 380.69 | 222.30 | 3.67 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 49.16 | -481.44 | 485.62 | 21.73 | -54.30 |
Cash at Beginning of Period | 104.14 | 585.58 | 99.96 | 78.23 | 132.53 |
Cash at End of Period | 153.30 | 104.14 | 585.58 | 99.96 | 78.23 |
Diluted Net EPS | 0.89 | 0.34 | 0.92 | 3.33 | -0.27 |
Fiscal Year End for Pacira BioSciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 27.87 | 8.98 | 41.96 | 17.09 | 6.23 |
Depreciation/Amortization & Depletion | 38.78 | 19.13 | 79.32 | 60.13 | 40.99 |
Net Change from Assets/Liabilities | 1.43 | 8.11 | -45.78 | -33.98 | -28.57 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 34.26 | 12.88 | 79.15 | 63.83 | 43.98 |
Net Cash From Operating Activities | 102.34 | 49.10 | 154.65 | 107.07 | 62.63 |
Property & Equipment | -4.43 | -2.84 | -15.16 | -13.36 | -9.97 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -26.32 | -12.69 | 92.70 | 82.53 | 83.48 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -30.75 | -15.53 | 77.54 | 69.17 | 73.51 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -23.64 | 0.00 | 4.75 | 3.61 | 3.59 |
Issuance (Repayment) of Debt | 82.24 | -2.81 | -180.76 | -177.95 | -150.14 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -36.44 | 0.00 | -7.02 | -6.91 | -6.91 |
Net Cash from Financing Activities | 22.16 | -2.82 | -183.03 | -181.25 | -153.47 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 93.76 | 30.75 | 49.16 | -5.02 | -17.33 |
Cash at Beginning of Period | 153.30 | 153.30 | 104.14 | 104.14 | 104.14 |
Cash at End of Period | 247.05 | 184.05 | 153.30 | 99.12 | 86.81 |
Diluted Net EPS | 0.39 | 0.19 | 0.58 | 0.23 | 0.51 |